Ichor Medical Systems, Inc. and Profectus BioSciences, Inc. Enter into an Agreement for Use of TriGrid(TM) Electroporation Device to Develop Multiple DNA Vaccines

SAN DIEGO & BALTIMORE--(BUSINESS WIRE)--Ichor Medical Systems (Ichor) and Profectus Biosciences (Profectus) announced today that they have entered into a long-term development, license, and supply Agreement providing Profectus with commercial access to Ichor’s TriGrid™ Delivery System (TriGrid™) for the clinical development of its DNA vaccine programs, with an option for Ichor to co-develop.

MORE ON THIS TOPIC